Panoplia Laboratories Inc
Programs
Synthetic Innate Immunity Program
The Synthetic Innate Immunity program aims to develop medicines that serve as society's first line of defense against emerging viral outbreaks by taking inspiration from natural mechanisms of innate immunity. By encoding natural or engineered pattern recognition receptors (PRRs) and interferon-stimulated genes (ISGs) in DNA delivered to the respiratory tract, the program works to persistently enhance a patient's natural sense-and-respond capacity, potentially providing prophylactic protection against a broad range of respiratory viruses for months. During the reporting period, the program achieved several key milestones: developing assays for testing antiviral activities of drug candidates, establishing capacity to deliver nucleic acids to mice, and developing capability to conduct influenza viral challenge studies in mice.GeographiesNot indicatedDatesJun 29, 2023 – May 31, 2024Source990No causes providedNo populations provided–$543K
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)